Skip to Content
Merck
All Photos(1)

Documents

SRP3110

Sigma-Aldrich

M-CSF human

Animal-component free, recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC), suitable for cell culture

Synonym(s):

CSF-1, MGI-IM, Macrophage Colony Stimulating Factor

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352202
NACRES:
NA.32

biological source

human

recombinant

expressed in E. coli

Assay

≥98% (HPLC)
≥98% (SDS-PAGE)

form

lyophilized

potency

≤1.0 ng/mL ED50

mol wt

36.8 kDa

packaging

pkg of 10 μg

technique(s)

cell culture | mammalian: suitable

impurities

<0.1 EU/μg endotoxin, tested

color

white to off-white

UniProt accession no.

shipped in

wet ice

storage temp.

−20°C

Gene Information

human ... CSF1(1435)

General description

M-CSF (macrophage colony-stimulating factor) is a potent hematopoietic factor produced by a variety of cells including lymphocytes, monocytes, fibroblasts, endothelial cells, myoblasts and osteoblasts. The protein works through its receptor CSF1R (colony stimulating factor 1 receptor). The human is reactive in murine systems, but the murine molecule exhibits no activity on human cells. Recombinant human M-CSF is a 36.8kDa homodimeric protein containing two 159 amino acid polypeptide subunits.

Application

M-CSF human has been used for the induction of osteoclastogenesis in human peripheral blood mononuclear cells.

Biochem/physiol Actions

M-CSF (macrophage colony-stimulating factor) is a key regulator of cellular proliferation, differentiation, and survival of blood monocytes, tissue macrophages and their progenitor cells. M-CSF has been shown to play important roles in modulating dermal thickness, and male and female fertility. M-CSF is clinically used in the treatment of infection, malignancies and atherosclerosis. It facilitates hematopoietic recovery after bone marrow transplantation. M-CSF also works as a pleiotropic growth factor and plays a crucial role in reproduction and organogenesis. Absence of it can result in reduced growth, neurological and reproductive problems, developmental defects in the mammary gland, bone and pancreas. M-CSF is also involved in the pathogenesis of cancer.

Sequence

MEEVSEYCSH MIGSGHLQSL QRLIDSQMET SCQITFEFVD QEQLKDPVCY LKKAFLLVQD IMEDTMRFRD NTPNAIAIVQ LQELSLRLKS CFTKDYEEHD KACVRTFYET PLQLLEKVKN VFNETKNLLD KDWNIFSKNC NNSFAECSSQ GHERQSEGS

Physical form

Lyophilized from 10 mM Sodium Phosphate, pH 8.0 + 75 mM NaCl.

Reconstitution

Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 0.1-1.0 mg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 week. For extended storage, it is recommended to further dilute in a buffer containing a stabilizer (example 5% Trehalose) and store in working aliquots at -20°C to -80°C.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

The inhibitory effect of microRNA-146a expression on bone destruction in collagen-induced arthritis.
Nakasa T, et al.
Arthritis and Rheumatism, 63, 1582-1590 (2011)
Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function.
Zavrski I, et al.
Biochemical and Biophysical Research Communications, 333, 200-205 (2005)
The macrophage colony-stimulating factor, CSF-1.
E R Stanley
Methods in enzymology, 116, 564-587 (1985-01-01)
M-CSF in a new biomarker panel with HE4 and CA 125 in the diagnostics of epithelial ovarian cancer patients.
Bedkowska GE, et al.
Journal of Ovarian Research, 8, 27-27 (2015)
Janis L Abkowitz et al.
Transplantation, 88(3), 323-329 (2009-08-12)
Lysosomal storage diseases are devastating illnesses, in large part because of their neurologic consequences. Because significant morbidity occurs prenatally, in utero (IU) therapy is an attractive therapeutic approach. We studied the feasibility and efficacy of IU injections of monocytic cells

Articles

Read article on hematopoietic cytokines and hematopoiesis

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service